[조사 보고서] 세계의 방사선 치료 시장 (~2028년) : 종류별 (제품, 서비스), 기술별 (MRI 리니악, 정위, 입자선 치료, 코발트 -60 원격 치료), 시술별 (IMRT, IGRT, 3D-CRT, LDR, HDR), 용도별 (전립선, 유방, 폐), 최종 용도별 (병원), 지역별

■ 영문 제목 : Radiotherapy Market by Type (Product, Service), Technology (MRI LINAC, Stereotactic, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT, 3D-CRT, LDR, HDR), Application (Prostate, Breast, Lung), End User (Hospital) & Region - Global Forecast to 2028
	■ 상품코드 : MD1773-23 ■ 조사/발행회사 : MarketsandMarkets ■ 발행일 : 2023년 11월 ■ 페이지수 : 277 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : Email (주문후 24시간내 납품) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 의료

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User	USD4,950 ⇒환산￦6,930,000	견적의뢰/주문/질문
Multi User (Five User)	USD6,650 ⇒환산￦9,310,000	견적의뢰/주문/질문
Corporate License	USD8,150 ⇒환산￦11,410,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

"글로벌 방사선 치료 시장은 2023년 6.9억 달러에서 2028년 8.8억 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 5.0%의 성장률을 기록할 것으로 예상됩니다.".전 세계 암 발병률 증가, 방사선 치료 기술의 발전, 전 세계 암 센터의 입자선 치료 채택 확대가 예측 기간 동안 방사선 치료 시장의 성장을 뒷받침할 것으로 보입니다.

"글로벌 방사선 치료 시장의 소프트웨어 및 서비스 부문이 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다."
방사선 치료 시장은 유형에 따라 제품과 소프트웨어 및 서비스로 구분됩니다. 소프트웨어 및 서비스 부문은 주로 북미와 유럽 등 기존 시장에서 높은 성장률을 기록할 것으로 예상됩니다. 방사선 치료의 발전과 보다 정확하고 개인화된 암 치료 계획에 대한 수요 증가는 혁신적인 방사선 치료 소프트웨어 및 서비스 개발로 이어지고 있습니다.

"기술별로는 외부 빔 방사선 치료 분야가 2022년 글로벌 방사선 치료 시스템 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다."
기술에 따라 방사선 치료 시장은 외부 빔 방사선 치료와 내부 빔 방사선 치료로 구분됩니다. 외부 빔 방사선 치료 (EBRT) 부문은 외부 빔 방사선 치료 기술의 광범위한 채택과 첨단 외부 빔 방사선 치료 기술의 개발 및 상용화를 위해 시장 플레이어가 연구 개발에 지속적으로 투자하고 있기 때문에 2022 년 방사선 치료에서 가장 큰 점유율을 차지했습니다.

"전립선암, 외부 빔 방사선 요법 용도별 2022년 가장 큰 시장 점유율을 차지할 것으로 예상됩니다."
방사선 치료 시장은 용도에 따라 외부 빔 방사선 치료 응용 분야와 내부 빔 방사선 치료/방사선 요법 응용 분야의 두 가지 주요 세그먼트로 분류됩니다. 외부 빔 방사선 치료 용도는 유방암, 전립선암, 두경부암, 폐암, 대장암, 기타 암으로 나뉩니다.

"체내 방사선 치료/소선량 치료의 용도는 전립선암, 부인과암, 유방암, 자궁경부암, 음경암, 기타 암(폐암, 두경부암)으로 세분화됩니다."
전립선암은 전 세계 전립선암 발병률 증가, 전립선암에 대한 외부 빔 방사선 치료의 이점, 전립선암 치료를 위한 방사선 치료 분야의 연구 활동 증가로 인해 2022년 전립선암이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

"방사선 치료 시장의 지역별 점유율은 북미가 가장 큽니다."
글로벌 방사선 치료 시장은 북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카의 5개 주요 지역으로 구분됩니다. 북미는 방사선 치료 제품 및 서비스의 가장 큰 지역 시장인 반면, 아시아 태평양 시장은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 추정됩니다. 북미의 최대 점유율은 첨단 방사선 치료 기술의 급속한 채택, 방사선 치료 소프트웨어 제조업체와 최종 사용자 간의 협력 관계 증가, 북미 각국의 다양한 의료 시설 및 서비스 네트워크의 존재, 이 지역의 암 치료를 지원하는 유리한 상환 모델에 기인합니다.

이번 보고서의 주요 참여 기업은 다음과 같습니다.
- 기업 유형별: 티어 1-48%, 티어 2-36%, 티어 3-16%.
- 직급별: C레벨 - 10%, 이사급 - 14%, 기타 - 76%.
- 지역별: 북미 40%, 유럽 32%, 아시아 태평양 20%, 중남미 5%, 중동 및 아프리카 3%.

방사선 치료 시장의 주요 업체로는 Siemens Healthcare GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA (Belgium), ViewRay Technologies, Inc. (US), C-RAD (Sweden), IBA Worldwide (Belgium), Hitachi Ltd. (Japan (US), Mevion Medical Systems (US), Optivus Proton Therapy, Inc. (US) 및 Panacea Medical Technologies Pvt. Ltd. (India)) 등이 있습니다.

조사범위:
이 보고서는 제품, 기술, 용도, 최종 사용자, 지역별로 방사선 치료 시장을 조사하고 있습니다. 또한 시장 성장에 영향을 미치는 요인을 다루고, 시장의 다양한 기회와 과제를 분석하여 시장 리더를 위한 경쟁 환경에 대한 세부 정보를 제공합니다. 또한, 개별 성장 추세와 관련하여 마이크로 시장을 분석하고 4개 주요 지역(및 각 국가)에 대한 시장 부문의 수익을 예측합니다.

보고서 구매 이유:
이 보고서는 기존 기업뿐만 아니라 신규 진입자 및 소규모 기업도 시장 동향을 파악하여 더 큰 시장 점유율을 확보하는 데 도움이 될 수 있습니다. 본 보고서를 구매한 기업은 아래 전략 중 하나 또는 여러 가지를 조합하여 시장에서의 입지를 강화할 수 있습니다.

이 보고서는 다음 사항에 대한 통찰력을 제공합니다.
- 방사선 치료 시장 성장에 영향을 미치는 주요 촉진 요인(기술 발전, 암 유병률 증가, 입자선 치료 이용 확대), 억제 요인(적절한 의료 서비스 부족, 자동화된 방사선 치료 시스템의 높은 비용, 숙련된 방사선 전문의 부족), 기회(개발도상국의 의료비 증가), 도전 과제(방사선 피폭 위험) ) 분석을 제공하고 있습니다.
 시장 침투: 방사선 치료 시장의 선두 기업들이 제공하는 제품 포트폴리오에 대한 포괄적인 정보를 제공합니다.
 제품 개발/혁신: 방사선 치료 시장의 미래 동향, R&D 활동, 제품 출시에 대한 상세한 통찰력을 제공합니다.
 시장 개발: 유망한 신흥 지역에 대한 포괄적인 정보를 제공합니다.
 시장 다각화: 방사선 치료 시장의 신제품, 성장 지역 및 최신 동향에 대한 포괄적인 정보를 제공합니다.
 경쟁 평가: 시장 부문, 성장 전략, 수익 분석, 주요 시장 플레이어의 제품에 대한 상세한 평가를 제공합니다.

■ 보고서 개요

1. 소개
2. 조사 방법
3. 개요
4. 프리미엄 인사이트
5. 시장 개요
6. 세계의 방사선 치료 시장 규모 : 제품 및 서비스별
7. 세계의 방사선 치료 시장 규모 : 기술별
8. 세계의 방사선 치료 시장 규모 : 용도별
9. 세계의 방사선 치료 시장 규모 : 치료법별
10. 세계의 방사선 치료 시장 규모 : 최종 용도별
11. 세계의 방사선 치료 시장 규모 : 지역별
12. 경쟁 현황
13. 기업 정보
14. 부록

■ 보고서 목차

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.2.1 INCLUSIONS AND EXCLUSIONS 36
1.3 STUDY SCOPE 37
1.3.1 MARKETS COVERED 37
1.3.2 REGIONS COVERED 38
1.3.3 YEARS CONSIDERED 38
1.3.4 CURRENCY CONSIDERED 38
1.4 KEY STAKEHOLDERS 39
1.5 SUMMARY OF CHANGES 39
1.6 RECESSION IMPACT 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
FIGURE 1 RESEARCH DESIGN 40
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY RESEARCH 42
2.1.2.1 Key data from primary sources 42
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 43
FIGURE 3 GLOBAL RADIOTHERAPY MARKET: BREAKDOWN OF PRIMARIES 43
2.2 MARKET SIZE ESTIMATION METHODOLOGY 43
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 44
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 44
2.2.2 USAGE-BASED MARKET ESTIMATION 45
FIGURE 5 MARKET SIZE ESTIMATION: GLOBAL RADIOTHERAPY MARKET 45
2.2.3 PRIMARY RESEARCH VALIDATION 46
2.3 DATA TRIANGULATION 47
FIGURE 6 DATA TRIANGULATION METHODOLOGY 47
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 48
2.4.1 RESEARCH ASSUMPTIONS 48
2.4.2 RESEARCH LIMITATIONS 48
2.5 RECESSION IMPACT ANALYSIS 48
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 48

3 EXECUTIVE SUMMARY 50
FIGURE 7 RADIOTHERAPY MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 8 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 51
FIGURE 9 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 10 RADIOTHERAPY MARKET SHARE, BY END USER, 2023 VS. 2028 52
FIGURE 11 RADIOTHERAPY MARKET: GEOGRAPHICAL SNAPSHOT 53
4 PREMIUM INSIGHTS 54
4.1 RADIOTHERAPY MARKET OVERVIEW 54
FIGURE 12 RISING CANCER PREVALENCE WORLDWIDE TO DRIVE GROWTH 54
4.2 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 55
4.3 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TECHNOLOGY AND REGION (2022) 55
FIGURE 13 LINACS HELD LARGEST SHARE IN 2O22 55
4.4 RADIOTHERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
FIGURE 14 CHINA TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
FIGURE 15 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57
5.2.1 DRIVERS 58
5.2.1.1 Advancements in radiotherapy treatment technology 58
5.2.1.2 Growing patient population 59
FIGURE 16 PROJECTED INCREASE IN CANCER CASES, 2020–2040 59
5.2.1.3 Increasing initiatives to promote radiotherapy awareness 59
5.2.1.4 Growing use of particle therapy for cancer treatment 60
5.2.2 RESTRAINTS 60
5.2.2.1 Lack of adequate healthcare infrastructure 60
5.2.2.2 High capital cost of radiotherapy 61
5.2.2.3 Complexity of radiotherapy 61
5.2.3 OPPORTUNITIES 62
5.2.3.1 Emerging economies 62
5.2.3.2 Favorable changes in US radiotherapy payment model 62
5.2.3.3 Government and private investments to meet rising demand for cancer treatment 63
5.2.4 CHALLENGES 63
5.2.4.1 Dearth of skilled personnel 63
5.2.4.2 Difficulties in visualizing tumors during radiotherapy 64
5.2.4.3 Risk of radiation exposure 64
5.3 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 2 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.3.1 THREAT OF NEW ENTRANTS 65
5.3.2 THREAT OF SUBSTITUTES 65
5.3.3 BARGAINING POWER OF SUPPLIERS 65
5.3.4 BARGAINING POWER OF BUYERS 65
5.3.5 DEGREE OF COMPETITION 66
5.4 REGULATORY LANDSCAPE 66
TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
5.4.1 NORTH AMERICA 67
5.4.1.1 US 67
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 68
5.4.2 CANADA 68
TABLE 7 CLASS II PRESCRIBED EQUIPMENT CERTIFICATES 68
5.4.3 EUROPE 69
5.4.4 ASIA PACIFIC 70
5.4.4.1 China 70
5.4.4.2 Japan 70
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 71
5.4.5 INDIA 71
5.5 REIMBURSEMENT SCENARIO 71
TABLE 9 CPT CODES FOR MAJOR RADIOTHERAPY TREATMENT MODALITIES 72
TABLE 10 REIMBURSEMENT FOR RADIOTHERAPY PROCEDURES PER COURSE, 2021 VS 2022 72
TABLE 11 OPPS TECHNICAL PER PROCEDURE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS 2022 73
TABLE 12 FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS 2022 73
5.6 ECOSYSTEM/MARKET MAP 74
5.7 VALUE CHAIN ANALYSIS 74
5.7.1 RESEARCH & DEVELOPMENT 74
5.7.2 PROCUREMENT AND PRODUCT DEVELOPMENT 74
5.7.3 MARKETING, SALES AND DISTRIBUTION, AND POST-SALES SERVICES 74
FIGURE 17 VALUE CHAIN ANALYSIS 75
5.8 SUPPLY CHAIN ANALYSIS 75
5.8.1 PROMINENT COMPANIES 75
5.8.2 SMALL & MEDIUM-SIZED ENTERPRISES 75
5.8.3 END USERS 76
FIGURE 18 SUPPLY CHAIN ANALYSIS 76
5.9 TRADE DATA 76
TABLE 13 IMPORT DATA FOR LINACS (HS CODE 902214), BY COUNTRY, 2017–2021 (USD MILLION) 76
TABLE 14 EXPORT DATA FOR LINACS (HS CODE 902214), BY COUNTRY, 2017–2021 (USD MILLION) 77
5.10 PRICING ANALYSIS 77
FIGURE 19 AVERAGE SELLING PRICES OF KEY PLAYERS FOR TOP TWO PRODUCTS 77
TABLE 15 AVERAGE SELLING PRICES OF KEY PLAYERS FOR TOP TWO PRODUCTS (USD) 78
TABLE 16 AVERAGE SELLING PRICE TRENDS 78
5.11 KEY CONFERENCES & EVENTS IN 2023–2025 78
TABLE 17 RADIOTHERAPY MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS 78
5.12 TECHNOLOGY ANALYSIS 80
5.13 PATENT ANALYSIS 81
FIGURE 20 TOP PATENT APPLICANTS FOR PROTON BEAM THERAPY, JANUARY 2012–OCTOBER 2023 81
FIGURE 21 TOP PATENT APPLICANTS FOR MEDICAL LINEAR ACCELERATORS, JANUARY 2012–OCTOBER 2023 82
5.14 CASE STUDY ANALYSIS 82
TABLE 18 CASE STUDY: ENHANCING PATIENT SAFETY—SBRT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC) 82
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 83
FIGURE 22 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 83
5.16 KEY STAKEHOLDERS & BUYING CRITERIA 83
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY SYSTEMS 83
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY DEVICES 84
5.16.2 BUYING CRITERIA 84
FIGURE 24 KEY BUYING CRITERIA FOR RADIOTHERAPY 84
TABLE 20 KEY BUYING CRITERIA FOR RADIOTHERAPY 84
6 RADIOTHERAPY MARKET, BY PRODUCT & SERVICE 85
6.1 INTRODUCTION 86
TABLE 21 RADIOTHERAPY MARKET, BY PRODUCT & SERVICE, 2022–2028 (USD MILLION) 86
6.2 PRODUCTS 86
6.2.1 CONTINUOUS DEVELOPMENT OF ADVANCED TECHNOLOGIES TO BOOST MARKET 86
TABLE 22 RADIOTHERAPY PRODUCTS MARKET, BY REGION, 2022–2028 (USD MILLION) 87

6.3 SOFTWARE & SERVICES 87
6.3.1 INCREASING DEMAND FOR PRECISE AND EFFECTIVE CANCER TREATMENT TO SUPPORT MARKET GROWTH 87
TABLE 23 RADIOTHERAPY SOFTWARE & SERVICES MARKET, BY REGION, 2022–2028 (USD MILLION) 88
7 RADIOTHERAPY MARKET, BY TECHNOLOGY 89
7.1 INTRODUCTION 90
TABLE 24 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 90
7.2 EXTERNAL BEAM RADIOTHERAPY 90
TABLE 25 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 90
TABLE 26 EXTERNAL BEAM RADIOTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 91
7.3 LINACS 91
TABLE 27 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 91
TABLE 28 LINACS MARKET, BY REGION, 2021–2028 (USD MILLION) 92
7.3.1 CONVENTIONAL LINACS 92
7.3.1.1 Long treatment duration to limit adoption 92
TABLE 29 CONVENTIONAL LINACS MARKET, BY REGION, 2021–2028 (USD MILLION) 92
7.3.2 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS 93
TABLE 30 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2021–2028 (USD MILLION) 93
TABLE 31 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY REGION, 2021–2028 (USD MILLION) 93
7.3.2.1 CyberKnife 94
7.3.2.1.1 Precise radiation delivery with robotic correction capabilities to drive market 94
TABLE 32 CYBERKNIFE MARKET, BY REGION, 2021–2028 (USD MILLION) 94
7.3.2.2 Gamma Knife 95
7.3.2.2.1 Ongoing product development and launches to support growth 95
TABLE 33 GAMMA KNIFE MARKET, BY REGION, 2021–2028 (USD MILLION) 95
7.3.2.3 TomoTherapy 96
7.3.2.3.1 High installation and maintenance costs to limit adoption 96
TABLE 34 TOMOTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 96
7.3.3 MRI LINACS 96
7.3.3.1 Real-time imaging advantage to propel growth 96
TABLE 35 MRI LINACS MARKET, BY REGION, 2022–2028 (USD MILLION) 97
7.4 PARTICLE THERAPY 97
TABLE 36 PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2021–2028 (USD MILLION) 97
TABLE 37 PARTICLE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 98
7.4.1 CYCLOTRONS 98
7.4.1.1 Enhanced outcomes and other advantages to boost adoption 98
TABLE 38 CYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 99
7.4.2 SYNCHROTRONS 99
7.4.2.1 Increasing investments in synchrotron facilities to drive market 99
TABLE 39 SYNCHROTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
7.4.3 SYNCHROCYCLOTRONS 100
7.4.3.1 High space requirements limit widespread adoption 100
TABLE 40 SYNCHROCYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
7.5 CONVENTIONAL COBALT-60 TELETHERAPY 101
7.5.1 COMPLEX DOSE DELIVERY PLANNING AND RADIATION EXPOSURE TO LIMIT MARKET ADOPTION 101
TABLE 41 CONVENTIONAL COBALT-60 TELETHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 101
7.6 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 102
TABLE 42 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 43 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 102
7.7 SEEDS 103
7.7.1 ADVERSE SIDE-EFFECTS ASSOCIATED WITH SEEDS TO LIMIT ADOPTION 103
TABLE 44 SEEDS MARKET, BY REGION, 2021–2028 (USD MILLION) 103
7.8 AFTERLOADERS 103
7.8.1 PROPER POSITIONING AND BETTER CONTROL OF ISOTOPES IN MODERN AFTERLOADERS TO DRIVE DEMAND 103
TABLE 45 AFTERLOADERS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
7.9 IORT SYSTEMS 104
7.9.1 RISING ADOPTION OF ELECTRONIC BRACHYTHERAPY PROCEDURES TO SUPPORT GROWTH 104
TABLE 46 IORT SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 105
7.10 APPLICATORS 105
7.10.1 HIGH RISK OF RADIATION EXPOSURE IN MANUAL APPLICATORS TO LIMIT GROWTH 105
TABLE 47 APPLICATORS MARKET, BY REGION, 2021–2028 (USD MILLION) 106
7.11 SYSTEMIC RADIOTHERAPY 106
7.11.1 HIGH RISK OF RADIATION EXPOSURE TO LIMIT ADOPTION 106
7.11.2 IOBENGUANE (I-131) 106
7.11.3 SAMARIUM-153 107
7.11.4 RHENIUM-186 107
7.11.5 OTHER SYSTEMIC RADIOTHERAPY PRODUCTS 107
8 RADIOTHERAPY MARKET, BY APPLICATION 108
8.1 INTRODUCTION 109
TABLE 48 RADIOTHERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 109
8.2 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS 109
TABLE 49 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 109
TABLE 50 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2028 (USD MILLION) 110
8.2.1 PROSTATE CANCER 110
8.2.1.1 High incidence rate and efficiency of EBRT in prostate cancer treatment to support growth 110
TABLE 51 EXTERNAL BEAM RADIOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 111
8.2.2 BREAST CANCER 111
8.2.2.1 Therapeutic benefits of EBRT to drive market 111
TABLE 52 EXTERNAL BEAM RADIOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 112
8.2.3 LUNG CANCER 112
8.2.3.1 High prevalence of lung cancer and efficiency of EBRT to drive market 112
TABLE 53 EXTERNAL BEAM RADIOTHERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 113
8.2.4 HEAD & NECK CANCER 113
8.2.4.1 Noninvasive treatment of head & neck cancers to drive market 113
TABLE 54 EXTERNAL BEAM RADIOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2021–2028 (USD MILLION) 113
8.2.5 COLORECTAL CANCER 114
8.2.5.1 High incidence of colorectal cancer to support market growth 114
TABLE 55 EXTERNAL BEAM RADIOTHERAPY MARKET FOR COLORECTAL CANCER, BY REGION, 2021–2028 (USD MILLION) 114
8.2.6 OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS 114
TABLE 56 OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2028 (USD MILLION) 115
8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 115
TABLE 57 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 115
TABLE 58 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 116
8.3.1 PROSTATE CANCER 116
8.3.1.1 Precision of brachytherapy to drive market 116
TABLE 59 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2022–2028 (USD MILLION) 117
8.3.2 GYNECOLOGICAL CANCER 117
8.3.2.1 Availability of alternatives to hinder adoption of brachytherapy 117
TABLE 60 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2021–2028 (USD MILLION) 118
8.3.3 BREAST CANCER 118
8.3.3.1 Wide usage as replacement for traditional EBRT to drive market 118
TABLE 61 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 119
8.3.4 CERVICAL CANCER 119
8.3.4.1 Effectiveness of combined brachytherapy-chemotherapy procedure to support adoption 119
TABLE 62 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR CERVICAL CANCER, BY REGION, 2021–2028 (USD MILLION) 120
8.3.5 PENILE CANCER 120
8.3.5.1 Rising awareness and effectiveness of brachytherapy to drive market 120
TABLE 63 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR PENILE CANCER, BY REGION, 2021–2028 (USD MILLION) 121
8.3.6 OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 121
TABLE 64 OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 122
9 RADIOTHERAPY MARKET, BY PROCEDURE 123
9.1 INTRODUCTION 124
TABLE 65 RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2028 (USD MILLION) 124
9.2 EXTERNAL BEAM RADIOTHERAPY 124
TABLE 66 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 67 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY REGION, 2021–2028 (USD MILLION) 125
9.2.1 IMRT 125
9.2.1.1 Advantages over 2D and 3D-CRT to boost adoption 125
TABLE 68 IMRT MARKET, BY REGION, 2021–2028 (USD MILLION) 126
9.2.2 IGRT 126
9.2.2.1 Growing demand in treating deep-seated tumors to drive market 126
TABLE 69 IGRT MARKET, BY REGION, 2021–2028 (USD MILLION) 127
9.2.3 3D CONFORMAL RADIOTHERAPY 127
9.2.3.1 High precision and minimized damage to nearby tissues to boost adoption 127
TABLE 70 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 128
9.2.4 SRT 128
9.2.4.1 Minimally invasive procedure to drive end-user preference 128
TABLE 71 SRT MARKET, BY REGION, 2021–2028 (USD MILLION) 129
9.2.5 PARTICLE THERAPY 129
9.2.5.1 High usage as primary mode of cancer treatment to sustain market growth 129
TABLE 72 PARTICLE THERAPY MARKET, BY REGION, 2022–2028 (USD MILLION) 130
9.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 130
TABLE 73 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 74 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY REGION, 2021–2028 (USD MILLION) 131
9.3.1 LDR BRACHYTHERAPY 131
9.3.1.1 Low risk of radiation exposure to surrounding tissues to drive adoption 131
TABLE 75 LDR BRACHYTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 132
9.3.2 HDR BRACHYTHERAPY 132
9.3.2.1 Possibility of tissue injury to affect adoption 132
TABLE 76 HDR BRACHYTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 132
9.3.3 PDR BRACHYTHERAPY 133
9.3.3.1 Combination of advantages to boost growth 133
TABLE 77 PULSED-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 133
9.4 SYSTEMIC RADIOTHERAPY 133
9.4.1 HIGH COST OF RADIOPHARMACEUTICALS AND RISK OF RADIATION EXPOSURE TO LIMIT USAGE 133
9.4.2 INTRAVENOUS RADIOTHERAPY 134
9.4.3 ORAL RADIOTHERAPY 134
9.4.4 INSTILLATION RADIOTHERAPY 134
10 RADIOTHERAPY MARKET, BY END USER 135
10.1 INTRODUCTION 136
TABLE 78 RADIOTHERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 136
10.2 HOSPITALS 136
10.2.1 HOSPITALS TO DOMINATE END-USER MARKET 136
TABLE 79 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 137
10.3 INDEPENDENT RADIOTHERAPY CENTERS 137
10.3.1 LOWER OPERATING COSTS AND CONVENIENCE TO SUPPORT MARKET GROWTH 137
TABLE 80 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2021–2028 (USD MILLION) 137
11 RADIOTHERAPY MARKET, BY REGION 138
11.1 INTRODUCTION 139
TABLE 81 RADIOTHERAPY MARKET, BY REGION, 2022–2028 (USD MILLION) 139
11.2 NORTH AMERICA 139
11.2.1 NORTH AMERICA: RECESSION IMPACT 139
FIGURE 25 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT 140
TABLE 82 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 141
TABLE 83 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 141
TABLE 84 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 141
TABLE 85 NORTH AMERICA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 142
TABLE 86 NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 142
TABLE 87 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 142
TABLE 88 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 143
TABLE 89 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 143
TABLE 90 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 144
TABLE 91 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 144
11.2.2 US 144
11.2.2.1 Changes in reimbursement scenario to drive market growth 144
TABLE 92 US: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 145
TABLE 93 US: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 146
TABLE 94 US: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 146
TABLE 95 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 146
11.2.3 CANADA 147
11.2.3.1 Growing prevalence of cancer to drive demand for radiotherapy 147
TABLE 96 CANADA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 147
TABLE 97 CANADA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 148
TABLE 98 CANADA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 148
TABLE 99 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 148
11.3 EUROPE 149
11.3.1 EUROPE: RECESSION IMPACT 149
TABLE 100 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 150
TABLE 101 EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 150
TABLE 102 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 150
TABLE 103 EUROPE: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 151
TABLE 104 EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 151
TABLE 105 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 151
TABLE 106 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 152
TABLE 107 EUROPE: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 152
TABLE 108 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 153
TABLE 109 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 153
11.3.2 GERMANY 153
11.3.2.1 Availability of novel radiotherapy products to drive market 153
TABLE 110 GERMANY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 154
TABLE 111 GERMANY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 155
TABLE 112 GERMANY: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 155
TABLE 113 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 155
11.3.3 FRANCE 156
11.3.3.1 High purchasing & maintenance costs of advanced radiotherapy systems to limit market growth 156
TABLE 114 FRANCE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 156
TABLE 115 FRANCE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 156
TABLE 116 FRANCE: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 157
TABLE 117 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 157
11.3.4 UK 157
11.3.4.1 High healthcare expenditure to drive market 157
TABLE 118 UK: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 158
TABLE 119 UK: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 158
TABLE 120 UK: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 159
TABLE 121 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 159
11.3.5 SPAIN 159
11.3.5.1 Growing research activities on cancer care drive market 159
TABLE 122 SPAIN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 160
TABLE 123 SPAIN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 161
TABLE 124 SPAIN: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 161
TABLE 125 SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 161
11.3.6 ITALY 162
11.3.6.1 High number of oncology-specific clinical trials & studies to support market growth 162
TABLE 126 ITALY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 162
TABLE 127 ITALY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 163
TABLE 128 ITALY: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 163
TABLE 129 ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 163
11.3.7 REST OF EUROPE 164
TABLE 130 REST OF EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 164
TABLE 131 REST OF EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 164
TABLE 132 REST OF EUROPE: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 165
TABLE 133 REST OF EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 165
11.4 ASIA PACIFIC 165
11.4.1 ASIA PACIFIC: RECESSION IMPACT 166
FIGURE 26 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT 167
TABLE 134 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 168
TABLE 135 ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 168
TABLE 136 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 169
TABLE 137 ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 169
TABLE 138 ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 170
TABLE 139 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 170
TABLE 140 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 171
TABLE 141 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 171
TABLE 142 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 172
TABLE 143 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 172
11.4.2 JAPAN 172
11.4.2.1 Rising geriatric population and cancer incidence to drive market 172
TABLE 144 JAPAN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 173
TABLE 145 JAPAN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 173
TABLE 146 JAPAN: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 174
TABLE 147 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 174
11.4.3 CHINA 174
11.4.3.1 Growing partnerships among market players to support growth 174
TABLE 148 CHINA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 175
TABLE 149 CHINA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 175
TABLE 150 CHINA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 176
TABLE 151 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 176
11.4.4 INDIA 176
11.4.4.1 High need for radiotherapy systems to provide opportunities 176
TABLE 152 INDIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 177
TABLE 153 INDIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 177
TABLE 154 INDIA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 178
TABLE 155 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 178
11.4.5 SOUTH KOREA 178
11.4.5.1 Increasing incidence of cancer to support market 178
TABLE 156 SOUTH KOREA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 179
TABLE 157 SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 179
TABLE 158 SOUTH KOREA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 180
TABLE 159 SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 180
11.4.6 AUSTRALIA 180
11.4.6.1 Availability of funding for cancer care & research to drive growth 180
TABLE 160 AUSTRALIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 181
TABLE 161 AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 181
TABLE 162 AUSTRALIA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 182
TABLE 163 AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 182
11.4.7 REST OF ASIA PACIFIC 182
TABLE 164 REST OF ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 183
TABLE 165 REST OF ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 183
TABLE 166 REST OF ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 184
TABLE 167 REST OF ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 184
11.5 LATIN AMERICA 184
11.5.1 LATIN AMERICA: RECESSION IMPACT 185
TABLE 168 LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 185
TABLE 169 LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 185
TABLE 170 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 186
TABLE 171 LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 186
TABLE 172 LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 186
TABLE 173 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 187
TABLE 174 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2023–2028 (USD MILLION) 187
TABLE 175 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 188
TABLE 176 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 188
TABLE 177 LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 189
11.5.2 BRAZIL 189
11.5.2.1 Restricted affordability & access to radiotherapy to challenge market growth 189
TABLE 178 BRAZIL: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 189
TABLE 179 BRAZIL: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 190
TABLE 180 BRAZIL: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 190
TABLE 181 BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 190
11.5.3 MEXICO 191
11.5.3.1 Rising target population to boost market growth 191
TABLE 182 MEXICO: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 191
TABLE 183 MEXICO: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 192
TABLE 184 MEXICO: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 192
TABLE 185 MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 192
11.5.4 REST OF LATIN AMERICA 193
TABLE 186 REST OF LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 193
TABLE 187 REST OF LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 193
TABLE 188 REST OF LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 194
TABLE 189 REST OF LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 194
11.6 MIDDLE EAST & AFRICA 194
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET 194
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 195
TABLE 190 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 195
TABLE 191 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 196
TABLE 192 MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 196
TABLE 193 MIDDLE EAST & AFRICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 196
TABLE 194 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 197
TABLE 195 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 197
TABLE 196 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 198
TABLE 197 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 198
TABLE 198 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 199
12 COMPETITIVE LANDSCAPE 200
12.1 OVERVIEW 200
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 200
FIGURE 27 OVERVIEW OF STRATEGIES ADOPTED BY KEY RADIOTHERAPY PLAYERS (2020 TO 2023) 201
12.3 REVENUE ANALYSIS 202
FIGURE 28 REVENUE ANALYSIS OF TOP FIVE PLAYERS, 2019–2022 202
12.4 MARKET SHARE ANALYSIS 202
FIGURE 29 RADIOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022 202
12.5 COMPANY EVALUATION MATRIX 203
12.5.1 STARS 203
12.5.2 EMERGING LEADERS 203
12.5.3 PERVASIVE PLAYERS 203
12.5.4 PARTICIPANTS 203
FIGURE 30 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX, 2022 204
12.5.5 COMPANY FOOTPRINT 205
TABLE 199 PRODUCT FOOTPRINT (18 COMPANIES) 205
TABLE 200 REGIONAL FOOTPRINT (18 COMPANIES) 206
TABLE 201 COMPANY FOOTPRINT (18 COMPANIES) 207
12.6 START-UP/SME EVALUATION MATRIX 207
12.6.1 PROGRESSIVE COMPANIES 207
12.6.2 RESPONSIVE COMPANIES 208
12.6.3 DYNAMIC COMPANIES 208
12.6.4 STARTING BLOCKS 208
FIGURE 31 RADIOTHERAPY MARKET: START-UP/SME EVALUATION MATRIX, 2022 208
12.6.5 COMPETITIVE BENCHMARKING 209
TABLE 202 RADIOTHERAPY MARKET: DETAILED LIST OF KEY START-UPS/SMES 209
12.7 COMPETITIVE SCENARIO AND TRENDS 210
12.7.1 PRODUCT LAUNCHES & APPROVALS 210
12.7.2 DEALS 210
12.7.3 OTHER DEVELOPMENTS 211

13 COMPANY PROFILES 212
(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS 212
13.1.1 SIEMENS HEALTHINEERS GMBH (VARIAN MEDICAL SYSTEMS, INC.) 212
TABLE 203 SIEMENS HEALTHINEERS GMBH: COMPANY OVERVIEW 212
FIGURE 32 SIEMENS HEALTHINEERS GMBH: COMPANY SNAPSHOT (2022) 213
13.1.2 ELEKTA 219
TABLE 204 ELEKTA: COMPANY OVERVIEW 219
FIGURE 33 ELEKTA: COMPANY SNAPSHOT (2022) 220
13.1.3 ACCURAY INCORPORATED 226
TABLE 205 ACCURAY INCORPORATED: COMPANY OVERVIEW 226
FIGURE 34 ACCURAY INCORPORATED: COMPANY SNAPSHOT (2023) 227
13.1.4 IBA WORLDWIDE (ION BEAM APPLICATIONS SA) 231
TABLE 206 IBA WORLDWIDE: COMPANY OVERVIEW 231
FIGURE 35 IBA WORLDWIDE: COMPANY SNAPSHOT (FY 2022) 232
13.1.5 VIEWRAY TECHNOLOGIES, INC. 236
TABLE 207 VIEWRAY TECHNOLOGIES, INC.: COMPANY OVERVIEW 236
FIGURE 36 VIEWRAY TECHNOLOGIES, INC.: COMPANY SNAPSHOT (FY 2022) 237
13.1.6 PERSPECTIVE THERAPEUTICS, INC. 241
TABLE 208 PERSPECTIVE THERAPEUTICS, INC.: COMPANY OVERVIEW 241
FIGURE 37 PERSPECTIVE THERAPEUTICS, INC.: COMPANY SNAPSHOT (FY 2022) 241
13.1.7 HITACHI LTD. 243
TABLE 209 HITACHI LTD.: COMPANY OVERVIEW 243
FIGURE 38 HITACHI LTD.: COMPANY SNAPSHOT (FY 2022) 244
13.1.8 SUMITOMO HEAVY INDUSTRIES LTD. 246
TABLE 210 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY OVERVIEW 246
FIGURE 39 SUMITOMO HEAVY INDUSTRIES: COMPANY SNAPSHOT (FY 2022) 247
13.1.9 CARL ZEISS MEDITEC AG 249
TABLE 211 CARL ZEISS MEDITEC AG: COMPANY OVERVIEW 249
FIGURE 40 CARL ZEISS MEDITEC AG: COMPANY SNAPSHOT (2021) 250
13.1.10 MIM SOFTWARE INC. 252
TABLE 212 MIM SOFTWARE INC.: COMPANY OVERVIEW 252
13.1.11 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 254
TABLE 213 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW 254
13.1.12 PROVISION HEALTHCARE 256
TABLE 214 PROVISION HEALTHCARE: COMPANY OVERVIEW 256
13.1.13 MEVION MEDICAL SYSTEMS 257
TABLE 215 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 257
13.1.14 OPTIVUS PROTON THERAPY, INC. 260

TABLE 216 OPTIVUS PROTON THERAPY: COMPANY OVERVIEW 260
13.1.15 P-CURE 261
TABLE 217 P-CURE: COMPANY OVERVIEW 261
13.1.16 INTRAOP MEDICAL, INC. 263
TABLE 218 INTRAOP MEDICAL, INC.: COMPANY OVERVIEW 263
13.1.17 BEBIG MEDICAL 264
TABLE 219 BEBIG MEDICAL: COMPANY OVERVIEW 264
13.1.18 KONINKLIJKE PHILIPS N.V. 266
TABLE 220 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 266
FIGURE 41 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 267
13.1.19 RAYSEARCH LABORATORIES 268
TABLE 221 RAYSEARCH LABORATORIES: COMPANY OVERVIEW 268
FIGURE 42 RAYSEARCH LABORATORIES: COMPANY SNAPSHOT (2022) 269
13.1.20 THERAGENICS 272
TABLE 222 THERAGENICS CORPORATION: COMPANY OVERVIEW 272
13.2 OTHER PLAYERS 273
13.2.1 PROTOM INTERNATIONAL 273
13.2.2 DOSISOFT SA 273
13.2.3 ISOAID 274
13.2.4 MAGNETTX ONCOLOGY SOLUTIONS LTD. 274
13.2.5 BRAINLAB AG 275
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 276
14.1 DISCUSSION GUIDE 276
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 282
14.3 CUSTOMIZATION OPTIONS 284
14.4 RELATED REPORTS 284
14.5 AUTHOR DETAILS 285

※본 조사보고서 [세계의 방사선 치료 시장 (~2028년) : 종류별 (제품, 서비스), 기술별 (MRI 리니악, 정위, 입자선 치료, 코발트 -60 원격 치료), 시술별 (IMRT, IGRT, 3D-CRT, LDR, HDR), 용도별 (전립선, 유방, 폐), 최종 용도별 (병원), 지역별] (코드 : MD1773-23) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 방사선 치료 시장 (~2028년) : 종류별 (제품, 서비스), 기술별 (MRI 리니악, 정위, 입자선 치료, 코발트 -60 원격 치료), 시술별 (IMRT, IGRT, 3D-CRT, LDR, HDR), 용도별 (전립선, 유방, 폐), 최종 용도별 (병원), 지역별] 에 대해서 E메일 문의는 여기를 클릭하세요.

*** 아래는 관련 보고서 소개입니다 ***

세계의 생명 과학 분석 시장 (~2027년)
HIT4869-23 / MarketsandMarkets / 2023년 2월 / 마켓츠앤마켓츠 (MarketsandMarkets)의 본 보고서는 세계의 생명 과학 분석 시장 규모가 2022년 271억 달러에 이르며, 2027년까지 475억 달러로 확대될 것으로 추정하고 있습니다. 덧붙여 예측 기간 동안 연평균 11.8%로 성장할 것으로 전망하고...“The life science analytics market is projected to reach USD 47.5 billion by 2027 from USD 27.1 billion in 2022, at a CAGR of 11.8% during the forecast period.” Growth in this market is mainly driven by rising pressure to curb healthcare spending, the rising need for improved data standardization,...

세계의 엑스레이 검사 시스템 시장 (~2028년) : 기술별 (필름 기반 이미징, 디지털 이미징, 컴퓨터 단층 촬영, 컴퓨터 방사선 촬영, 직접 방사선 촬영), 차원별 (2D, 3D), 산업별 (정부 인프라, 자동차), 지역별
SE5476-23 / MarketsandMarkets / 2023년 10월 / "세계의 엑스레이 검사 시스템 시장은 2023년 8억 달러에서 2028년 11억 달러에 이르며, 예측 기간 중 CAGR은 6.2%를 기록할 것으로 전망됩니다."식품 산업에서의 안전성과 품질에 대한 주목의 증가, 회로 기판 실장의 고밀도화,...1. 소개 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 엑스레이 검사 시스템 시장 분석 : 기술별 7. 세계의 엑스레이 검사 시스템 시장 분석 : 차원별 8. 세계의 엑스레이 검사 시스템 시장 분석 : 산업별 9. 세계의 엑스레이 검사 시스템 시장 분석 : 지역별 10....

세계의 CAR-T 세포 치료 시장 (~2029년) : 제품별 (아메크마, 브레얀지, 카빅티, 예스카타, 테카투스, 킴리아), 표적 항원별 (CD19, BCMA), 질환별 (다발성 골수종, 백혈병, 림프종), 인구 통계별 (성인, 소아), 최종 용도별, 지역별
PH9093 / MarketsandMarkets / 2024년 7월 / ...“글로벌 CAR T 세포 치료 시장은 2024년 55억 달러에서 2029년에는 290억 달러에 이를 것으로 예상되며, 2024~2029년 예측 기간 동안 39.6%의 연평균 성장률(CAGR)을 기록할 것으로 전망됩니다.”시장 성장은 전 세계 암 유병률의 증가에 의해 주도되고 있습니다. CAR T세포 치료제의 기술 발전과 치료법 개발 투자 및 자금 증가가 시장 성장을 촉진할 것으로 보입니다....

세계의 동물 유전학 시장 (~2029년) : 동물별 (소, 돼지), 제품 및 서비스별 (유전자 재료, 유전자 검사 서비스), 기술별 (PCR, NGS, rDNA, 마이크로어레이 기술), 최종 사용자별 (동물 농장, 동물 병원 및 진료소)
BT 3244 / MarketsandMarkets / 2024년 12월 / ...“세계 동물 유전학 시장은 2024년 29.7억 달러에서 2029년에는 41.9억 달러에 이를 것으로 예상되며, 예측 기간 중 연평균 성장률은 7.1%” 고급 유전자 검사 기술의 채택, 동물복지에 대한 관심 증가, 반려동물에 대한 수요 증가와 더불어 동물 유전학 시장의 성장을 견인하고 있습니다. 이러한 성장은 가축 생산성 향상, 더 나은 번식 방법, 동물 관리...

글로벌 바이오 폴리프로필렌 시장 (~2029) : 원료별, 최종 용도별, 용도별, 지역별
CH 9281 / MarketsandMarkets / 2025년 1월 / ...바이오 폴리프로필렌 시장은 2024년 32,480,000달러로 평가되었으며, 2029년까지 1,16,028,000달러에 이를 것으로 예상되며, 2024년부터 2029년까지 연평균 29.0% 성장할 것으로 전망됩니다. 환경에 대한 인식, 규제 조치, 기술 혁신으로 인해 전 세계 바이오 폴리프로필렌 시장은 빠른 속도로 성장하고 있습니다. 기후 변화와 오염에 대한 사회적 불안이 커지면서 소비자와 산업계는 기존 플라스틱을 대체할 지속 가능한 대체재를...

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!